Name | Sodium (3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate |
---|---|
Synonyms |
3-Isoquinolinecarboxylic acid, 2-(2,2-diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-, sodium salt, (3S)- (1:1)
Sodium (3S)-5-(benzyloxy)-2-(diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate MFCD30502664 |
Description | Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons[1][2][3][4]. |
---|---|
Related Catalog | |
Target |
"Reverse Transcriptase[1] HIV[1]" |
In Vivo | EMA401 sodium(10mg/kg;口服)导致慢性压迫性损伤 (CCI) 后第 14 天大鼠的 θ 功率显着减弱和缩爪潜伏期 (PWL) 增加[4]。 |
References |
Molecular Formula | C32H28NNaO5 |
---|---|
Molecular Weight | 529.56 |
Exact Mass | 529.186523 |